Colorcon launches on-dose authentication technology platform

23 Dec 2019

Next-generation pharmaceutical supply-chain security for tracking product from plant to patient.

Colorcon has announced the development and availability of On-Dose Authentication capability to provide track and trace functionality for supply chain security.

Colorcon launches on-dose authentication technology platform

The seamless integration of molecular taggants from Applied DNA Sciences (ADNAS) into an Opadry fully formulated film coating system significantly reduces the risks associated with counterfeit and falsified medications entering the supply chain.

This first commercial offering is the culmination of extensive collaboration between Colorcon and ADNAS to help pharmaceutical companies enhance patient safety and reduce risk by using intelligent data and analytics gathered from authentication of the dosage form itself. By better understanding the vulnerabilities of a complex global supply chain, drug manufacturers can make informed decisions regarding distribution networks and deploy preventative measures to address counterfeiting and product diversion issues.

Dr Ali Rajabi-Siahboomi, Vice President/Chief Scientific Officer at Colorcon said: “With new guidelines from regulators and accessible technology, on-dose solutions provide a more robust and reliable means of identifying and deterring counterfeiting, verifying product authenticity, and ensuring product traceability. Through extensive research and development, Colorcon has created a unique coating system to address this global problem.”

Kelly Boyer, General Manager, Film Coatings at Colorcon explained: “On-dose authentication technology represents the next generation in pharmaceutical supply-chain security by providing a powerful tool for tracking product from plant to patient. By seamlessly enabling authentication, these digitized coatings confirm the quality and origin of medicines thereby safeguarding both patients and brands.”

Read More

Related news

UPDATED: COVID-19 PHARMA TRACKER

UPDATED: COVID-19 PHARMA TRACKER

27 Mar 2020

The latest coronavirus updates and developments impacting the global pharmaceutical supply chain…

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Helsinn receives European approval of its IV formulation of Akynzeo

Helsinn receives European approval of its IV formulation of Akynzeo

23 Mar 2020

The new formulation offers patients in Europe an alternative route of administration of the only fixed antiemetic combination targeting two distinct CINV pathways in a single dose.

Read more 
Lonza's new medium boosts and optimizes AAV production in insect cells

Lonza's new medium boosts and optimizes AAV production in insect cells

23 Mar 2020

The TheraPEAK SfAAV Medium is specifically designed to support the development of safe, scalable, gene therapies.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Oxford Biomedica signs LSA with Juno Therapeutics

Oxford Biomedica signs LSA with Juno Therapeutics

19 Mar 2020

Cell and gene focused CDMO Oxford Biomedica (OXB) has signed a licence and clinical supply agreement which could be worth up to USD227 million with Juno Therapeutics, the firms announced Wednesday.

Read more 
FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

FDB to triple UK microbial production capacity as Fujifilm commits to $83 million investment

19 Mar 2020

Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.

Read more